Related Experiment Video
Updated: Jan 27, 2026

Detection of Horizontal Gene Transfer Mediated by Natural Conjugative Plasmids in E. coli
Published on: March 24, 2023
Natural product-drug conjugates for modulation of TRPV1-expressing tumors
Charlotte Baker1, Tiago Rodrigues1, Bernardo P de Almeida1
1Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
Abstract:
We report the design, synthesis and biological evaluation of natural product-drug conjugates for treatment of prostate cancers over-expressing the transient receptor potential vanilloid 1 (TRPV1) channel. We validate the relevance of TRPV1 as a target in prostate cancer patients by using a bioinformatics approach and provide proof-of-concept for the drug delivery strategy through bioorthogonal chemistry and stability assays under simulated physiological conditions. In cell-based assays, the constructs displayed modest activity. Moreover, we serendipitously discover that a stoichiometric combination of a TRPV1 agonist with a small, positively charged cytotoxic may provide new research avenues in personalized medicines for prostate cancer.
Insights
Researchers developed novel drug conjugates targeting prostate cancer by leveraging the transient receptor potential vanilloid 1 (TRPV1) channel. A serendipitous discovery suggests a new approach for personalized prostate cancer medicine.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Prostate cancer often over-expresses the transient receptor potential vanilloid 1 (TRPV1) channel.
- TRPV1 is a potential therapeutic target for prostate cancer treatment.
- Targeted drug delivery strategies are needed to improve treatment efficacy.
Purpose of the Study:
- To design, synthesize, and evaluate natural product-drug conjugates for prostate cancer treatment.
- To validate TRPV1 as a therapeutic target in prostate cancer.
- To demonstrate the feasibility of a bioorthogonal drug delivery system.
Main Methods:
- Bioinformatics analysis to assess TRPV1 relevance in prostate cancer.
- Synthesis of natural product-drug conjugates.
- Bioorthogonal chemistry and stability assays.
- Cell-based assays to evaluate conjugate activity.
Main Results:
- TRPV1 relevance as a target was validated in prostate cancer patients.
- The drug delivery strategy was proven feasible under physiological conditions.
- Synthesized conjugates showed modest activity in cell-based assays.
- A combination of TRPV1 agonist and cytotoxic agent showed potential.
Conclusions:
- Natural product-drug conjugates targeting TRPV1 are a viable strategy for prostate cancer.
- Bioorthogonal chemistry enables effective drug delivery for cancer therapy.
- A novel combination therapy approach may offer new avenues for personalized prostate cancer medicine.
Related Concept Videos
Drug Product Stability
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Conjugated Proteins
Drug Products: Biologics, Biosimilars and Interchangeables
What is Natural Selection?
Conjugation

